Suppr超能文献

基于人群的筛查项目和荟萃分析:风险评估和粪便免疫化学试验在结直肠癌筛查中的诊断准确性。

Diagnostic accuracy of risk assessment and fecal immunochemical test in colorectal cancer screening: Results from a population-based program and meta-analysis.

机构信息

Department of Epidemiology, Fudan University School of Public Health, Shanghai, China.

Yiwu Research Institute, Fudan University, Yiwu, China.

出版信息

Cancer Med. 2023 Sep;12(17):18189-18200. doi: 10.1002/cam4.6399. Epub 2023 Aug 14.

Abstract

BACKGROUND

Fecal immunochemical test (FIT) is a commonly used initial test for colorectal cancer (CRC) screening. Parallel use of FIT with risk assessment (RA) could improve the detection of non-bleeding lesions, but at the expense of compromising sensitivity. In this study, we evaluated the accuracy of FIT and/or RA in the Shanghai CRC screening program, and systematically reviewed the relevant evaluations worldwide.

METHODS

RA and 2-specimen FIT were used in parallel in the Shanghai screening program, followed by a colonoscopy among those with positive results. Sensitivity, specificity, detection rate of CRC, positive predictive value (PPV), and other measures with their 95% confident intervals were calculated for each type of tests and several assumed combined tests. We further searched PubMed, Embase, Web of Science, and Cochrane Library for relevant studies published in English up to January 5, 2022.

RESULTS

By the end of 2019, a total of 1,901,360 participants of the screening program completed 3,045,108 tests, with 1,901,360 first-time tests and 1,143,748 subsequent tests. Parallel use of RA and 2-specimen FIT achieved a sensitivity of 0.78 (0.77-0.80), a specificity of 0.78 (0.78-0.78), PPV of 0.89% (0.86-0.92), and a detection rate of 1.99 (1.93-2.05) for CRC per 1000 among participants enrolled in the first screening round, and performed similarly among those who participated for several times. A meta-analysis of 103 published observational studies demonstrated a higher sensitivity [0.76 (0.36, 0.94)] but a much lower specificity [0.59 (0.28, 0.85)] of parallel use of RA and FIT for detecting CRC in average-risk populations than in our subjects. One-specimen FIT, the most commonly used initial test, had a pooled specificity comparable to the Shanghai screening program (0.92 vs. 0.91), but a much higher pooled sensitivity (0.76 vs. 0.57).

CONCLUSION

Our results indicate the limitation of FIT only as an initial screening test for CRC in Chinese populations, and highlight the higher sensitivity of parallel use of RA and FIT. Attempts should be made to optimize RA to improve effectiveness of screening in the populations.

摘要

背景

粪便免疫化学检测(FIT)是一种常用的结直肠癌(CRC)筛查初始检测方法。FIT 与风险评估(RA)并行使用可以提高非出血性病变的检出率,但会降低敏感性。本研究评估了 FIT 和/或 RA 在上海 CRC 筛查项目中的准确性,并对全球相关评估进行了系统综述。

方法

上海筛查项目中平行使用 RA 和 2 份 FIT,阳性结果者进行结肠镜检查。计算每种检测方法及几种假定联合检测方法的敏感性、特异性、CRC 检出率、阳性预测值(PPV)等指标及其 95%置信区间。我们进一步在 PubMed、Embase、Web of Science 和 Cochrane Library 中检索截至 2022 年 1 月 5 日发表的英文相关研究。

结果

截至 2019 年底,筛查项目共纳入 1901360 名参与者,完成 3045108 次检测,其中 1901360 次为首次检测,1143748 次为后续检测。RA 和 2 份 FIT 并行使用时,首次筛查参与者的 CRC 敏感性为 0.78(0.77-0.80),特异性为 0.78(0.78-0.78),PPV 为 0.89%(0.86-0.92),检出率为 1.99(1.93-2.05)/1000;多次筛查参与者的结果相似。对 103 项已发表观察性研究的荟萃分析表明,RA 和 FIT 并行使用在一般风险人群中检测 CRC 的敏感性较高[0.76(0.36,0.94)],但特异性较低[0.59(0.28,0.85)],低于本研究人群。作为最常用的初始检测方法,1 份 FIT 的汇总特异性与上海筛查项目相当(0.92 比 0.91),但汇总敏感性更高(0.76 比 0.57)。

结论

本研究结果表明,FIT 作为中国人群 CRC 筛查的初始检测方法存在局限性,RA 和 FIT 并行使用的敏感性更高。应尝试优化 RA 以提高人群筛查效果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2dc6/10524075/84cb0973a836/CAM4-12-18189-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验